BRPI0718522A2 - Uso de um composto, e, método de tratamento para reduzir os níveis de triglicerídeo, colesterol e/ou glicose no sangue - Google Patents

Uso de um composto, e, método de tratamento para reduzir os níveis de triglicerídeo, colesterol e/ou glicose no sangue Download PDF

Info

Publication number
BRPI0718522A2
BRPI0718522A2 BRPI0718522-7A BRPI0718522A BRPI0718522A2 BR PI0718522 A2 BRPI0718522 A2 BR PI0718522A2 BR PI0718522 A BRPI0718522 A BR PI0718522A BR PI0718522 A2 BRPI0718522 A2 BR PI0718522A2
Authority
BR
Brazil
Prior art keywords
compound
formula
cholesterol
glucose levels
treatment
Prior art date
Application number
BRPI0718522-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Angelo Guglielmotti
Giuseppe Biondi
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of BRPI0718522A2 publication Critical patent/BRPI0718522A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mixers Of The Rotary Stirring Type (AREA)
BRPI0718522-7A 2006-11-24 2007-11-13 Uso de um composto, e, método de tratamento para reduzir os níveis de triglicerídeo, colesterol e/ou glicose no sangue BRPI0718522A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT002254A ITMI20062254A1 (it) 2006-11-24 2006-11-24 Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
ITMI2006A002254 2006-11-24
PCT/EP2007/009908 WO2008061671A2 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels

Publications (1)

Publication Number Publication Date
BRPI0718522A2 true BRPI0718522A2 (pt) 2013-11-12

Family

ID=38198404

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0718522-7A BRPI0718522A2 (pt) 2006-11-24 2007-11-13 Uso de um composto, e, método de tratamento para reduzir os níveis de triglicerídeo, colesterol e/ou glicose no sangue

Country Status (23)

Country Link
US (2) US8198310B2 (enExample)
EP (2) EP2409698B1 (enExample)
JP (1) JP5192490B2 (enExample)
KR (1) KR101413616B1 (enExample)
CN (1) CN101541323B (enExample)
AR (1) AR063894A1 (enExample)
AU (1) AU2007323351B2 (enExample)
BR (1) BRPI0718522A2 (enExample)
CA (1) CA2666371C (enExample)
CY (1) CY1116664T1 (enExample)
DK (2) DK2097080T3 (enExample)
EA (1) EA016885B1 (enExample)
ES (2) ES2530623T3 (enExample)
GE (1) GEP20125570B (enExample)
IL (1) IL198286A (enExample)
IT (1) ITMI20062254A1 (enExample)
MX (1) MX2009004295A (enExample)
PL (2) PL2097080T3 (enExample)
PT (2) PT2097080E (enExample)
SG (1) SG176508A1 (enExample)
SI (2) SI2409698T1 (enExample)
UA (1) UA97123C2 (enExample)
WO (1) WO2008061671A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
CN102471282A (zh) 2009-08-03 2012-05-23 方济各安吉利克化学联合股份有限公司 1-苄基-3-羟甲基-1h-吲唑及其衍生物以及所需镁中间体的制备方法
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
WO2015173786A1 (en) * 2014-05-15 2015-11-19 Boyd Shelley Romayne Compositions and methods for treating and diagnosing ocular disorders
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives
WO2021263246A1 (en) 2020-06-27 2021-12-30 Crescenta Biosciences Novel cell metabolism modulating compounds and uses thereof
US12138243B2 (en) 2021-12-31 2024-11-12 Crescenta Biosciences Antiviral use of FABP4 modulating compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131779B (it) * 1980-07-29 1986-06-25 Acraf Sale dell'acido (1-benzil-1h-indazol-3-il)-ossiacetico con la lisina e procedimento per la sua preparazione
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
IT1253703B (it) 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
IT1276031B1 (it) * 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
IT1293794B1 (it) 1997-07-28 1999-03-10 Acraf Farmaco attivo nel ridurre la produzione di proteina mcp-1
AU766219B2 (en) * 1998-02-02 2003-10-09 1149336 Ontario Inc. Method of regulating glucose metabolism, and reagents related thereto
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
US20060030582A1 (en) * 2002-04-29 2006-02-09 Demartino Julie Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
CA2605900A1 (en) 2005-04-29 2006-11-09 Nycomed Gmbh Mutual prodrug compounds for use as antiinflammatory agents with gastrointestinal protective activity
JP5368801B2 (ja) * 2005-12-01 2013-12-18 フリンダーズ パートナーズ ピーティワイ リミテッド 膵炎を予防および／または治療するための方法および組成物
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca

Also Published As

Publication number Publication date
EP2097080A2 (en) 2009-09-09
EP2409698A1 (en) 2012-01-25
PT2409698E (pt) 2015-02-10
AR063894A1 (es) 2009-02-25
SI2409698T1 (sl) 2015-04-30
SI2097080T1 (sl) 2013-05-31
SG176508A1 (en) 2011-12-29
ES2403584T3 (es) 2013-05-20
IL198286A (en) 2016-03-31
HK1165275A1 (en) 2012-10-05
IL198286A0 (en) 2010-02-17
GEP20125570B (en) 2012-07-10
CY1116664T1 (el) 2017-03-15
WO2008061671A3 (en) 2008-11-27
EP2097080B1 (en) 2013-02-20
WO2008061671A2 (en) 2008-05-29
HK1129071A1 (en) 2009-11-20
US20100069456A1 (en) 2010-03-18
JP2010510263A (ja) 2010-04-02
CA2666371A1 (en) 2008-05-29
US8846745B2 (en) 2014-09-30
US20120283307A1 (en) 2012-11-08
MX2009004295A (es) 2009-05-05
ES2530623T3 (es) 2015-03-04
CN101541323B (zh) 2012-01-04
EA200970506A1 (ru) 2009-10-30
PL2097080T3 (pl) 2013-07-31
PL2409698T3 (pl) 2015-06-30
KR101413616B1 (ko) 2014-07-01
AU2007323351B2 (en) 2013-05-02
DK2409698T3 (en) 2015-04-27
EP2409698B1 (en) 2015-01-21
CN101541323A (zh) 2009-09-23
AU2007323351A1 (en) 2008-05-29
CA2666371C (en) 2014-05-06
US8198310B2 (en) 2012-06-12
UA97123C2 (uk) 2012-01-10
DK2097080T3 (da) 2013-05-21
JP5192490B2 (ja) 2013-05-08
EA016885B1 (ru) 2012-08-30
ITMI20062254A1 (it) 2008-05-25
KR20090081410A (ko) 2009-07-28
PT2097080E (pt) 2013-04-01

Similar Documents

Publication Publication Date Title
JP6387010B2 (ja) 血中グルコースレベルを制御することによる糖尿病及び関連容態の処置のための組成物、方法及び使用
BRPI0718522A2 (pt) Uso de um composto, e, método de tratamento para reduzir os níveis de triglicerídeo, colesterol e/ou glicose no sangue
US10617689B2 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
CN106659701A (zh) 用于治疗年龄相关性症状和疾病的酮基丁酸酯化合物和组合物
WO2000035867A1 (en) Novel ligands of nuclear receptor
PT1680112E (pt) N-(5-adamantano-1-il-metoxi-pentil)desoxinojirimicina ou um seu sal aceite na indústria farmacêutica para ser usado no tratamento da resistência à insulina
EP3925610A1 (en) Composition and method for treating metabolic disorders
US20050250671A1 (en) Activators of peroxisome proliferator-activated receptor
HK1165275B (en) Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition
HK1129071B (en) Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2493 DE 16-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI